Abstract:Immune checkpoint blockade (ICB) therapy has been considered as an effective way to boost immune cells to recognize and attack tumors. However, side effects known as immune-related adverse events (irAEs) should be carefully managed. Here, we engineer immunosuppressive nanoparticles by coating PD-L1 overexpressed mesenchymal stem cells (MSCs) plasma membrane on poly lactic-co-glycolic acid nanoparticles (MSC-PD-L1+ NPs) for managing and reducing irAEs induced by immune checkpoint inhibitors. The nanoparticles can enrich at liver site after intravenous administration. In the high dose of anti-PD-L1 mAb-induced irAEs clinically relevant mouse model, a low dose of MSC-PD-L1+ NPs (2 mg/kg) sufficiently rescues hepatitis by inactivating T cells and macrophages in the liver tissue. More intriguingly, due to the dose threshold for nanoparticles to the tumor site, we unexpectedly find that the injected NPs do not affect the efficiency of ICB therapy to inhibit solid tumor growth. Such a strategy shows potential for managing the various cancer immunotherapy associated irAEs in clinical applications.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.1c02391?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.1c02391</a>.Characterization of MSCs and MSC-PD-L1+ NPs (Figures S1–S4); evaluation of interactions between MSC-PD-L1+ NPs and RAW264.7 cells (Figures S5 and S6); blood circulation of MSC-PD-L1+ NPs (Figure S7); co-localization of CD45+ lymphocytes and Cy5.5-labeled MSC-PD-L1+ NPs or MSC NPs in mouse liver (Figures S8 and S9); in vivo treatment evaluation of LPS-induced hepatitis mice (Figures S10 and S11); in vivo treatment evaluation of aPD-L1-induced hepatitis mice (Figures S12 and S13); effects of ultralow dosage of MSC-PD-L1+ NPs on B16F10 tumor growth (Figure S14); evaluation of different doses of MSC-PD-L1+ NPs for management of irAEs on mice bearing a B16F10 tumor (Figures S15 and S16) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.1c02391/suppl_file/nn1c02391_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Polysaccharide Mycophenolate-Based Nanoparticles for Enhanced Immunosuppression and Treatment of Immune-Mediated Inflammatory Diseases

Immunomodulatory Nanoparticles Mitigate Macrophage Inflammation via Inhibition of PAMP Interactions and Lactate-Mediated Functional Reprogramming of NF-κB and p38 MAPK

EFFECTS OF CRUDE POLYSACCHARIDES EXTRACT FROM MYTILUS EDULIS ON THE IMMUNE FACTORS IN IMMUNOSUPPRESSED MICE

Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver

Mycophenolic Acid Derivatives With Immunosuppressive Activity From The Coral-Derived Fungus Penicillium Bialowiezense

Inflammation-Targeted Biomimetic Nano-Decoys via Inhibiting the Infiltration of Immune Cells and Effectively Delivering Glucocorticoids for Enhanced Multiple Sclerosis Treatment

Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus

Ingenious Synergy of a Pathology-Specific Biomimetic Multifunctional Nanoplatform for Targeted Therapy in Rheumatoid Arthritis

UHPLC-MS-Based Metabolomics Reveal the Potential Mechanism of Armillaria mellea Acid Polysaccharide in and Its Effects on Cyclophosphamide-Induced Immunosuppressed Mice

Immunoenhancement of Edible Fungal Polysaccharides (Lentinan, Tremellan, and Pachymaran) on Cyclophosphamide-Induced Immunosuppression in Mouse Model

Macrophage membrane-coated Eucommia ulmoides polysaccharides-loaded PLGA nanoparticles as an effective antigen-targeted delivery system

Inflammation‐Targeted Biomimetic Nano‐Decoys via Inhibiting the Infiltration of Immune Cells and Effectively Delivering Glucocorticoids for Enhanced Multiple Sclerosis Treatment

Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil

MULTIPLE HYPOTHESES TESTING IN SMALL MICROARRAY EXPERIMENTS

A Novel Nanomedicine Ameliorates Acute Inflammatory Bowel Disease by Regulating Macrophages and T-Cells

Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis

The Structural Characterization and Immunomodulatory Activity of Polysaccharides from Pleurotus abieticola Fruiting Bodies

[Pegylated interferon alfa-induced psoriasis].

Precision Delivery of Dual Immune Inhibitors Loaded Nanomodulator to Reverse Immune Suppression for Combinational Photothermal-Immunotherapy

Developing Software Online With Platform-as-a-Service Technology

A polysaccharide from Pleurotus citrinopileatus mycelia enhances the immune response in cyclophosphamide-induced immunosuppressed mice via p62/Keap1/Nrf2 signal transduction pathway